The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DSNKY | -31.12% | -32.58% | -7.58% | +248% |
| S&P | +14.08% | +93.57% | +14.12% | +447% |
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.40B | 13.5% |
| Gross Profit | $2.34B | 0.1% |
| Gross Margin | 68.85% | -9.2% |
| Market Cap | $41.50B | -34.0% |
| Market Cap / Employee | $2.10M | 0.0% |
| Employees | 19.8K | 5.5% |
| Net Income | $307.27M | -25.2% |
| EBITDA | $426.23M | -42.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.67B | -25.8% |
| Accounts Receivable | $4.18B | 12.3% |
| Inventory | 4.1K | 30.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $682.13M | -3.5% |
| Short Term Debt | $679.85M | 24211.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 7.95% | -0.2% |
| Return On Invested Capital | 8.96% | 1.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$207.00M | -1137.2% |
| Operating Free Cash Flow | $57.97M | -72.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 32.65 | 22.93 | 22.05 | 22.31 | -41.23% |
| Price to Book | 4.56 | 4.35 | 3.99 | 3.80 | -35.36% |
| Price to Sales | 4.41 | 3.57 | 3.37 | 3.13 | -41.50% |
| Price to Tangible Book Value | 5.64 | 5.57 | 5.07 | 4.84 | -31.45% |
| Price to Free Cash Flow TTM | 17.01 | 19.84 | 25.52 | 22.25 | - |
| Enterprise Value to EBITDA | 93.89 | 61.20 | 51.71 | 92.06 | 16.58% |
| Free Cash Flow Yield | 5.9% | 5.0% | 3.9% | 4.5% | - |
| Return on Equity | 15.0% | 17.6% | 18.3% | 16.7% | 10.60% |
| Total Debt | $645.39M | $1.04B | $1.39B | $1.36B | 91.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
